205 related articles for article (PubMed ID: 30592148)
1. Transcriptome analysis of differentially expressed genes and pathways associated with mitoxantrone treatment prostate cancer.
Li S; Li R; Ma Y; Zhang C; Huang T; Zhu S
J Cell Mol Med; 2019 Mar; 23(3):1987-2000. PubMed ID: 30592148
[TBL] [Abstract][Full Text] [Related]
2. Identification of key genes and specific pathways potentially involved in androgen-independent, mitoxantrone-resistant prostate cancer.
Zhu S; Jiang L; Wang L; Wang L; Zhang C; Ma Y; Huang T
Cancer Manag Res; 2019; 11():419-430. PubMed ID: 30655694
[TBL] [Abstract][Full Text] [Related]
3. Regulatory effects of antitumor agent matrine on FOXO and PI3K-AKT pathway in castration-resistant prostate cancer cells.
Li Q; Huang H; He Z; Sun Y; Tang Y; Shang X; Wang C
Sci China Life Sci; 2018 May; 61(5):550-558. PubMed ID: 29119376
[TBL] [Abstract][Full Text] [Related]
4. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
Fang E; Zhang X; Wang Q; Wang D
Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
[TBL] [Abstract][Full Text] [Related]
5. Involvement of apoptotic pathways in docosahexaenoic acid-induced benefit in prostate cancer: Pathway-focused gene expression analysis using RT
Sun Y; Jia X; Hou L; Liu X; Gao Q
Lipids Health Dis; 2017 Mar; 16(1):59. PubMed ID: 28330470
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.
Li C; Sun H; Wei W; Liu Q; Wang Y; Zhang Y; Lian F; Liu F; Li C; Ying K; Huo H; Qi Z; Li B
Cell Oncol (Dordr); 2020 Dec; 43(6):1099-1116. PubMed ID: 32710433
[TBL] [Abstract][Full Text] [Related]
7. Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
Ye Y; Li SL; Wang SY
PLoS One; 2018; 13(8):e0198055. PubMed ID: 30138363
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
9. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
10. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
11. KAT5 and KAT6B are in positive regulation on cell proliferation of prostate cancer through PI3K-AKT signaling.
He W; Zhang MG; Wang XJ; Zhong S; Shao Y; Zhu Y; Shen ZJ
Int J Clin Exp Pathol; 2013; 6(12):2864-71. PubMed ID: 24294372
[TBL] [Abstract][Full Text] [Related]
12. DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.
Huber RM; Lucas JM; Gomez-Sarosi LA; Coleman I; Zhao S; Coleman R; Nelson PS
Oncotarget; 2015 Feb; 6(4):2134-47. PubMed ID: 25575823
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase.
Gesmundo I; Di Blasio L; Banfi D; Villanova T; Fanciulli A; Favaro E; Gamba G; Musuraca C; Rapa I; Volante M; Munegato S; Papotti M; Gontero P; Primo L; Ghigo E; Granata R
Cancer Lett; 2019 May; 449():252-262. PubMed ID: 30790678
[TBL] [Abstract][Full Text] [Related]
14. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B
Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
[TBL] [Abstract][Full Text] [Related]
15. Illumina whole-genome complementary DNA-mediated annealing, selection, extension and ligation platform: assessing its performance in formalin-fixed, paraffin-embedded samples and identifying invasion pattern-related genes in oral squamous cell carcinoma.
Loudig O; Brandwein-Gensler M; Kim RS; Lin J; Isayeva T; Liu C; Segall JE; Kenny PA; Prystowsky MB
Hum Pathol; 2011 Dec; 42(12):1911-22. PubMed ID: 21683979
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
17. A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.
Brady L; Gil da Costa RM; Coleman IM; Matson CK; Risk MC; Coleman RT; Nelson PS
Prostate; 2020 May; 80(6):491-499. PubMed ID: 32068909
[TBL] [Abstract][Full Text] [Related]
18. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
Liu Z; Zhu G; Getzenberg RH; Veltri RW
J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
[TBL] [Abstract][Full Text] [Related]
19. THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway.
Hou Y; Li H; Huo W
Prostate; 2020 Jul; 80(10):753-763. PubMed ID: 32421868
[TBL] [Abstract][Full Text] [Related]
20. Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
Chen S; Wang J; Wang L; Peng H; Xiao L; Li C; Lin D; Yang K
Exp Cell Res; 2019 Dec; 385(1):111669. PubMed ID: 31605696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
